Compare NEU & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEU | BLCO |
|---|---|---|
| Founded | 1887 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.7B |
| IPO Year | N/A | 2022 |
| Metric | NEU | BLCO |
|---|---|---|
| Price | $765.38 | $16.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $17.31 |
| AVG Volume (30 Days) | 72.6K | ★ 424.4K |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 5.10 | N/A |
| EPS | ★ 47.34 | N/A |
| Revenue | $2,744,413,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | N/A | $8.08 |
| Revenue Next Year | N/A | $5.77 |
| P/E Ratio | $16.19 | ★ N/A |
| Revenue Growth | N/A | ★ 6.23 |
| 52 Week Low | $480.00 | $10.45 |
| 52 Week High | $875.97 | $20.71 |
| Indicator | NEU | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 63.46 |
| Support Level | $744.62 | $16.73 |
| Resistance Level | $775.00 | $17.70 |
| Average True Range (ATR) | 20.54 | 0.52 |
| MACD | 1.52 | 0.14 |
| Stochastic Oscillator | 61.81 | 73.77 |
NewMarket Corp is a holding company that, through its subsidiaries, manufactures and sells petroleum additives. Petroleum additives are used in lubricating oils and fuels to enhance their performance in machinery, vehicles, and other equipment. It comprises two broad product applications. Lubricant additives are formulated chemical solutions that, when blended with base fluids, improve the efficiency, durability, performance, and functionality of mineral oils, synthetic oils, and biodegradable fluids. Fuel additives are chemical components that help oil refiners meet fuel specifications or formulated packages that improve the performance of gasoline, diesel, biofuels, and other fuels.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.